´Ù¹ß°ñ¼öÁ¾¿¬±¸È¸ Update on MM 2019 : 2019-02-09±³À°ÀÏÀÚ : 2019-02-09
±³À°Àå¼Ò : °¡Å縯´ëÇб³ ¼¿ï¼º¸ðº´¿ø ÁöÇÏ 1Ãþ ´ë°´ç
±³À°ÁÖÁ¦ :
Update on MM 2019ÁÖÃÖ±â°ü : ´ëÇÑÇ÷¾×ÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : ´Ù¹ß°ñ¼öÁ¾¿¬±¸È¸
´ã´çÀÚ : ¼È¿Áø
¿¬¶ôó : 02-516-6581
À̸ÞÀÏ :
hematology@kams.or.kr ±³À°Á¾·ù : ³»°ú, Áø´Ü°Ë»çÀÇÇаú
Âü¼®¿¹»óÀοø : 100¸í
Èñ¸ÁÆòÁ¡ : 5Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 5 ½Ã°£ 0ºÐ
¼¼ºÎ¼ö°·á : 0¿ø
ºñ°í
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 02-09 °¡Å縯´ëÇб³ ¼¿ï¼º¸ðº´¿ø ÁöÇÏ1Ãþ ´ë°´ç 10:30~11:00 Genomics/epigenomics in MM °í¿µÀÏ(¼¿ïÀÇ´ë)
±³À°½Ã°£ 02-09 °¡Å縯´ëÇб³ ¼¿ï¼º¸ðº´¿ø ÁöÇÏ1Ãþ ´ë°´ç 11:00~11:30 Cytogenetics/risk factors ±èº´¼ö(ÇѸ²ÀÇ´ë)
±³À°½Ã°£ 02-09 °¡Å縯´ëÇб³ ¼¿ï¼º¸ðº´¿ø ÁöÇÏ1Ãþ ´ë°´ç 11:30~12:00 Microenvironment in MM ¾ÈÁ¤¿(°¡ÃµÀÇ´ë)
±³À°½Ã°£ 02-09 °¡Å縯´ëÇб³ ¼¿ï¼º¸ðº´¿ø ÁöÇÏ1Ãþ ´ë°´ç 12:00~12:30 MRD/myeloma stem cell ¹ÚÈñ¼ö(ÃæºÏÀÇ´ë)
±³À°½Ã°£ 02-09 °¡Å縯´ëÇб³ ¼¿ï¼º¸ðº´¿ø ÁöÇÏ1Ãþ ´ë°´ç 13:30~14:00 Clinical Trials for NDMM - Transplant eligible ÃÖÀ±¼®(Ãæ³²ÀÇ´ë)
±³À°½Ã°£ 02-09 °¡Å縯´ëÇб³ ¼¿ï¼º¸ðº´¿ø ÁöÇÏ1Ãþ ´ë°´ç 14:00~14:30 Clinical Trials for transplantation,consolidation, maintenance ±è´ë½Ä(°í·ÁÀÇ´ë)
±³À°½Ã°£ 02-09 °¡Å縯´ëÇб³ ¼¿ï¼º¸ðº´¿ø ÁöÇÏ1Ãþ ´ë°´ç 14:40~15:10 Clinical Trials for NDMM - transplantatoin ineligible Çö½Å¿µ(¿øÁÖÀÇ´ë)
±³À°½Ã°£ 02-09 °¡Å縯´ëÇб³ ¼¿ï¼º¸ðº´¿ø ÁöÇÏ1Ãþ ´ë°´ç 15:10~15:40 Clinical Trials for R/R MM - IMIDs & PI ÀÌÀ¯Áø(°æºÏÀÇ´ë)
±³À°½Ã°£ 02-09 °¡Å縯´ëÇб³ ¼¿ï¼º¸ðº´¿ø ÁöÇÏ1Ãþ ´ë°´ç 15:50~16:20 Immunologic treatment I (MoAbs & novel agent) È«Á¤¿ë(¿ï»êÀÇ´ë)
±³À°½Ã°£ 02-09 °¡Å縯´ëÇб³ ¼¿ï¼º¸ðº´¿ø ÁöÇÏ1Ãþ ´ë°´ç 16:20~16:50 Immunologic treatment II (CAR-T & checkpoint inhibitors) Á¤¼ºÈÆ(Àü³²ÀÇ´ë)